WO2011036328A3 - Method for early detection of resistance to antiretroviral therapy in hiv - Google Patents

Method for early detection of resistance to antiretroviral therapy in hiv Download PDF

Info

Publication number
WO2011036328A3
WO2011036328A3 PCT/ES2010/070619 ES2010070619W WO2011036328A3 WO 2011036328 A3 WO2011036328 A3 WO 2011036328A3 ES 2010070619 W ES2010070619 W ES 2010070619W WO 2011036328 A3 WO2011036328 A3 WO 2011036328A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
therapy
early detection
antiretroviral therapy
resistance
Prior art date
Application number
PCT/ES2010/070619
Other languages
Spanish (es)
French (fr)
Other versions
WO2011036328A2 (en
Inventor
Pilar Perez Romero
Julian Mier Mota
Jeronimo Pachon Diaz
Luis F. Lopez Cortes
Pompeyo Viciana Fernandez
Original Assignee
Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla
Universidad De Sevilla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla, Universidad De Sevilla filed Critical Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla
Publication of WO2011036328A2 publication Critical patent/WO2011036328A2/en
Publication of WO2011036328A3 publication Critical patent/WO2011036328A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a pair of primers capable of amplifying the pol gene of the human immuno deficiency virus (HIV), allowing the detection of HIV in biological samples that exhibit a low viral load. The HIV RNA thus detected may be genotyped in order subsequently to establish a mutation profile showing resistance to antiretroviral therapy (ART) in HIV, in patients presenting a low viral load, to be used for the early detection of mutations which, in HIV, are responsible for the failure of ART, even in cases where plasma viremia levels are low, which makes it possible to modify the therapy early on to prevent the appearance of new mutations and to safeguard the efficacy of drugs in the current therapy regimen and of others that might be administered in the future.
PCT/ES2010/070619 2009-09-25 2010-09-24 Method for early detection of resistance to antiretroviral therapy in hiv WO2011036328A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200930737 2009-09-25
ES200930737A ES2376094B1 (en) 2009-09-25 2009-09-25 METHOD OF EARLY DETECTION OF RESISTANCES TO ANTIRRETROVIRAL TREATMENT IN HIV.

Publications (2)

Publication Number Publication Date
WO2011036328A2 WO2011036328A2 (en) 2011-03-31
WO2011036328A3 true WO2011036328A3 (en) 2011-07-14

Family

ID=43796298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2010/070619 WO2011036328A2 (en) 2009-09-25 2010-09-24 Method for early detection of resistance to antiretroviral therapy in hiv

Country Status (2)

Country Link
ES (1) ES2376094B1 (en)
WO (1) WO2011036328A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111560480A (en) * 2020-06-01 2020-08-21 昆明市官渡区妇幼保健计划生育服务中心 Method for detecting HIV-1 drug resistance of pregnant and lying-in women

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271354B1 (en) * 1997-04-03 2001-08-07 Thomas Jefferson University Chimeric viral proteins
US7537765B2 (en) * 2003-01-29 2009-05-26 Panacos Pharmaceuticals, Inc. Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271354B1 (en) * 1997-04-03 2001-08-07 Thomas Jefferson University Chimeric viral proteins
US7537765B2 (en) * 2003-01-29 2009-05-26 Panacos Pharmaceuticals, Inc. Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RHEE, S.Y.. ET AL.: "Predictive Value of HIV-1 Genotypic Resistance Test Interpretation Algorithms.", J INECT DIS, vol. 200, no. 83, 2009, pages 453 - 463 *

Also Published As

Publication number Publication date
WO2011036328A2 (en) 2011-03-31
ES2376094B1 (en) 2013-02-28
ES2376094A1 (en) 2012-03-09

Similar Documents

Publication Publication Date Title
WO2009059318A3 (en) Genes and polymorphisms associated with amd
WO2007144720A3 (en) Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients
WO2010093843A3 (en) Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
MD20170014A2 (en) Methods for the treatment of hepatitis B and hepatitis D virus infections
SG178909A1 (en) Generation of a broad t-cell response in humans against hiv
Grebely et al. Genetics of spontaneous clearance of hepatitis C virus infection: a complex topic with much to learn
AP2012006179A0 (en) ion and treatment of DNA based viruses in humans aPicrorhiza kurroa extract for prevention, eliminatnd in biotech industry.
WO2011036328A3 (en) Method for early detection of resistance to antiretroviral therapy in hiv
WO2007077465A3 (en) Treatment of hiv
WO2010016087A3 (en) Mutated sequences of hepatitis virus b related to drug resistance, method for their evaluation and use thereof in the medical field
Ward et al. Rilpivirine/tenofovir/emtricitabine fixed‐dose combination is an efficacious and well‐tolerated “switch” regimen for patients on therapy
GB201008123D0 (en) Novel compounds
SALOU et al. Challenges of scale-up to Dolutegravir based regimens in sub-Saharan Africa: a case study in Togo.
WO2009091586A3 (en) Peptides and methods of use as therapeutics and screening agents
杨明 Human immunodeficiency virus infection and inter-arm blood pressure difference
Varghese Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide
Pugliese et al. Observational study on HIV‐1‐infected patients treated with an ARV combination therapy including raltegravir: the RACING cohort results at month 12
Hajabdulbaghy et al. The prevalence of drug resistance in patients with HIV/AIDS attending to Imam Khomeini Hospital in Tehran, Iran during 2008-2009: letter to editor
Novitsky et al. Correction for Novitsky et al., Long-range HIV genotyping using viral RNA and proviral DNA for analysis of HIV drug resistance and HIV clustering
Trevino Development of resistance in HIV type 2: case report
谷斌 Relationship between hepatitis C virus genotypes and viral load in Chenzhou, China
JOH et al. Prevalence Of Multidrug-Resistant Mycobacterium Tuberculosis Among Locally Treated Human Immunodeficiency Virus-Infected Patients
Lohman III Assessment of Balance and Postural Control
Patel Telaprevir: high risk of drug interactions
EP2458019A3 (en) Methods and compositions for determining resistance of HIV-1 to protease inhibitors

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10818454

Country of ref document: EP

Kind code of ref document: A2